Toxicity Reporting in CAR-T

Slides:

Advertisements

Similar presentations

1 RIDER and MIRC R… I… D… E… R… Medical Imaging Resource Center.

Advertisements

Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.

Self-Report Measures of Functional Status and Quality of Life: Adults Sandra A. Mitchell, CRNP, M.Sc.N., AOCN National Institutes of Health Bethesda, MD.

American Society for Blood and Marrow Transplantation Promoting Research Priorities Helen Heslop.

Research Bioethics Consultation: More potential than sequencing genomes Benjamin S. Wilfond MD Seattle Children’s Hospital Treuman Katz Center for Pediatric.

Tang G et al. Proc SABCS 2010;Abstract S4-9.

New Approaches for Addressing Long Term Survivorship in Transplant Patients Dennis L. Confer, M.D. Chief Medical Officer National Marrow Donor Program.

What would you recommend as first line therapy for a 68 y/o woman with advanced pancreatic cancer and limited metastatic disease with ECOG-1? Gemcitabine.

5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].

Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.

The President’s Cancer Panel 2004/2005 Series Translating Research to Reduce the Burden of Cancer Margaret L. Kripke, Ph.D. January 25, 2005.

Which Myelofibrosis Patients are Candidates for Upfront Stem Cell Transplantation? Vikas Gupta, MD, FRCP, FRCPath The Elizabeth and Tony Comper MPN Program.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Developing and Implementing Intervention Studies Using Geriatric Assessment Supriya Gupta Mohile, M.D., M.S. Assistant Professor of Medicine James Wilmot.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Fractionated Dosing Optimizes CAR T-Cell Therapy in Adult Relapsed/Refractory.

(Donor T-Cells Transduced with iC9 Suicide Gene)

ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL New Findings in Hematology: Independent Conference.

: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma

The Teen and Young Adult Program at MSKCC

Vose JM et al. Proc ASH 2011;Abstract 661.

Lymph Node Dissection for Renal Cell Carcinoma: When, How and Why?

19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL

Maury S et al. Proc ASH 2015;Abstract 1.

F. Edward Boas, MD, PhD Memorial Sloan Kettering Cancer Center

ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -

Acute Stroke Therapy with IV Thrombolysis Lawrence R. Wechsler, M.D.

CCO Independent Conference Highlights

NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,

Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective.

Hematopoietic Cell Transplantation: Moving Beyond Survival to the Patient’s Perspective Linda J Burns, MD Medical Director, NMDP/Be The Match Health.

S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-

ASBMT Quality Outcomes Committee

Isabelle Lousada What a Patient Driven Multi-Stakeholder Organisation Can Do and Achieve. The Case of the ARC.

Miguel-Angel Perales MD

Stephanie J. Lee, Loretta A. Williams

Immunotherapy for lymphoma: The time is now

Relevant Financial Disclosure(s)

Fenaux P et al. Lancet Oncol 2009;10(3):

Figure 2 Three-step approach to the assessment and management

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.

Stephen Ansell, MD, PhD Mayo Clinic

ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors Shahrukh K. Hashmi, Stephanie J.

Conflict of Interest Disclosure (over the past 24 months)

Beyond Erlotinib: Better EGFR Inhibitors?

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Grövdal M et al. Blood 2008;112:Abstract 223.

Radiation Therapy for Prostate Cancer

An Introduction to NRG Oncology

CAR-T cells: New HOPE FOR CANCER PATIENTS

ASBMT Notes Biology of Blood and Marrow Transplantation

Stephanie J. Lee, Loretta A. Williams

Chronic graft-versus-host disease

Daniel J. Lenihan et al. BTS 2016;1:

Biology of Blood and Marrow Transplantation

Proposal to Delay the HCC Exception Score Assignment

Anas Younes, M.D. Memorial Sloan Kettering Cancer Center

G. Michael Felker et al. JCHF 2014;2:

CLL - When to treat, how to treat

Nat. Rev. Clin. Oncol. doi: /nrclinonc

by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal:

Timing for HCT Consultation

Patient Engagement through Social Media for Clinical Trials

Cytokine profiles can predict severe CRS

Care Team Collaboration for CAR T-Cell Therapy: Real-World Advice

Biology of Blood and Marrow Transplantation

Systemic inflammation in patients with severe neurotoxicity (NTX).

Increased blood–CSF barrier permeability during neurotoxicity (NTX).

Presentation transcript:

Toxicity Reporting in CAR-T Miguel Angel Perales MD Adult Bone Marrow Transplantation Service Memorial Sloan Kettering Cancer Center 2019 TCT Meeting Houston – February 21 2019

Miguel Perales MD Disclosures: Member, Scientific Advisory Board: MolMed, NexImmune Ad hoc Advisory Board: Abbvie, Bellicum, Incyte, Nektar Therapeutics, Novartis Member, DSMB: Medigene, Servier Consulting: Merck Research Funding: Incyte (clinical trial), Miltenyi (clinical trial) Academic/Not-for-Profit: Board Member: ASBMT, Be The Match (NMDP) CIBMTR Advisory Committee Tufts Cancer Center DSMB, University of Barcelona CAR T trial DSMB

Important Issues to Address in Establishing Mechanism for Long-term Follow-up of Cellular Therapy All Patients All Data Quality Long-term Follow-up Confidential Secure Compliant Available Cost Effective

What Data should we collect? Who do we report to? How do we report Data?

What Data should we collect? VS.

What Data should we collect?

Lee, Santomasso et al, BBMT 2018

ASBMT Cytokine Release Syndrome (CRS) Consensus Grading for Adults Lee, Santomasso et al, BBMT 2018

ASBMT Neurotoxicity (NT) – ICE Score Consensus Grading for Adults Lee, Santomasso et al, BBMT 2018

ASBMT Neurotoxicity (NT) – ICE Score Consensus Grading for Adults Lee, Santomasso et al, BBMT 2018

ASBMT Neurotoxicity (NT) – ICANS Grade Consensus Grading for Adults Lee, Santomasso et al, BBMT 2018

The ASBMT Mobile App

The ASBMT Mobile App

IEC Toxicity and Status Assessment – MSK Experience How do we report Data? IEC Toxicity and Status Assessment – MSK Experience

Design similar to GvHD notes with Clinical and Consensus options Mandated Weekly Clinical Assessments to day 28 Option for Event-Driven Assessment (i.e. CRS or Neurotox)